Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2007-06-19
2007-06-19
Chan, Christina (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C530S330000
Reexamination Certificate
active
11300169
ABSTRACT:
An immune response is modulated by selectively inhibiting ERAAP (an acronym for ER aminopeptidase associated with antigen processing) and confirming a resultant immune response modulation. More particularly, the method comprises contacting a patient determined to be in need of immune response modulation with a physiologically acceptable dosage composition comprising an effective amount of an inhibitor of ERAAP activity; confirming a resultant inhibition of said ERAAP activity and confirming a resultant immune response modulation in the patient. A variety of selective inhibitors are shown to be effective, including amino thiols, such as leucine thiol, ERAAP-specific antibody complementarity-determining region, and an ERAAP-specific siRNA.
REFERENCES:
patent: 7005269 (2006-02-01), Shastri et al.
Hattori et al, Biol Pharm Bull 27(6): 777-780, 2004.
Saveanu et at, Molecular Immunology 39: 203-215, 2002.
Serwold Thomas
Shastri Nilabh
Chan Christina
Huynh Phuong
Osman Richard Aron
Regents of the University of California
LandOfFree
ERAAP modulators regulate immune responses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with ERAAP modulators regulate immune responses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ERAAP modulators regulate immune responses will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3861924